Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research

Annals of the Rheumatic Diseases

Volumn 77, Issue 2, 2018, Pages 241-250

  McCann, Liza J ^a   Pilkington, Clarissa A ^b,c   Huber, Adam M ^d   Ravelli, Angelo ^e   Appelbe, Duncan ^f   Kirkham, Jamie J ^f   Williamson, Paula R ^f   Aggarwal, Amita ^g   Christopher Stine, Lisa ^h   Constantin, Tamas ⁱ   Feldman, Brian M ^j   Lundberg, Ingrid ^k   Maillard, Sue ^b   Mathiesen, Pernille ^l   Murphy, Ruth ^m   Pachman, Lauren M ^n,o,p   Reed, Ann M ^q   Rider, Lisa G ^r   Van Royen Kerkof, Annet ^s   Russo, Ricardo ^t   Spinty, Stefan ^a   Wedderburn, Lucy R ^u,v   Beresford, Michael W ^a,f   more..

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d IWK HEALTH CENTRE   (Canada)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l NAESTVED HOSPITAL   (Denmark)

^m ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

^o CHILDREN'S MEMORIAL HOSPITAL   (United States)

^p Stanley Manne Children's Research Institute   (United States)

^q DUKE UNIVERSITY   (United States)

^r NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^s UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^t Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^u UNIVERSITY COLLEGE LONDON   (United Kingdom)

^v NIHR Biomedical Research Centre at GOSH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; DELPHI STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE REGISTRY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HUMAN; INFORMATION PROCESSING; JUVENILE DERMATOMYOSITIS; MEDICAL RESEARCH; MYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; ADOLESCENT; CHILD; CONSENSUS; DERMATOMYOSITIS; FACTUAL DATABASE; PROCEDURES; RESEARCH;

ADOLESCENT; CHILD; CONSENSUS; DATA COLLECTION; DATABASES, FACTUAL; DELPHI TECHNIQUE; DERMATOMYOSITIS; HUMANS; RESEARCH;

EID: 85041537394     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-212141     Document Type: Article

References (49)

1. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 2010;62:63-72.
2. Mathiesen PR, Zak M, Herlin T, et al. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin Exp Rheumatol 2010;28:782-9.
3. Sanner H, Kirkhus E, Merckoll E, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res 2010;62:1103-11.
4. Meyer A, Meyer N, Schaeffer M, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 2015;54:50-63.
5. Lundberg IE, Svensson J. Registries in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2013;25:729-34.
6. Rider LG, Dankó K, Miller FW. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. Curr Opin Rheumatol 2014;26:724-41.
7. Rider LG, Giannini EH, Harris-Love M, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17.
8. Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/ European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2017;76:782-91.
9. National Institutes of Environmental Health and Science. International Myositis Assessment & Clinical Studies Group (IMACS). https://www. niehs. nih. gov/ research/ resources/ imacs/ index. cfm (accessed 8 Apr 2017).
10. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003;42:1452-9.
11. Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res 2010;62:1533-41.
12. PR INTO . Paediatric Rheumatology INternational Trials Organization. https://www. printo. it/ (accessed 8 Apr 2017).
13. McCann LJ, Arnold K, Pilkington CA, et al. Developing a provisional, international minimal dataset for juvenile dermatomyositis: for use in clinical practice to inform research. Pediatr Rheumatol Online J 2014;12:31.
14. McCann LJ, Kirkham JJ, Wedderburn LR, et al. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. Trials 2015;16:268.
15. Core Outcome Measures in Effectiveness Trials Initiative. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM); a rare but severe, potentially life-threatening childhood rheumatological condition. http://www. comet-initiative. org/ studies/ details/ 389? result= true (accessed 8 Apr 2017).
16. Kirkham JJ, Gorst S, Altman DG, et al. Core outcome set-STAndards for reporting: the COS-STAR statement. PLoS Med 2016;13:e1002148.
17. CARRA. Childhood Arthritis and Rheumatology Research Alliance. https:// carragroup. org/ (accessed 8 Apr 2017).
18. Euromyositis. International collaboration research and treatment database for myositis specialists. https:// euromyositis. eu/ (accessed 8 Apr 2017).
19. Martin N, Krol P, Smith S, et al. Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology 2011;50:137-45.
20. JDRG. Juvenile Dermatomyositis Research Group. h ttps ://www. juveniledermatomy osit is. org. uk/ (accessed 8 Apr 2017).
21. PReS. Paediatric Rheumatology European Society. http://www. pres. eu/ (accessed 8 Apr 2017).
22. Rider L, Werth V, Huber A, et al. Measures for adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Red 2013;63:118-57.
23. Varnier GC, Ferrari C, Consolaro A, et al. PReS-FINAL-2012: introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report. Pediatric Rheumatol 2013;11:P25.
24. Hullmann SE, Ryan JL, Ramsey RR, et al. Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL-R, Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales, and Quality of My Life Questionnaire (QoML). Arthritis Care Res 2011;63:S420-30.
25. van Agt HM, Essink-Bot ML, Krabbe PF, et al. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med 1994;39:1537-44.
26. Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2:169-80.
27. Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol 2014;28:331-50.
28. Cure JM Foundation. http://www. curejm. org/ (accessed 8 Apr 2017).
29. Myositis UK. http://www. myositis. org. uk/ (accessed 8 Apr 2017).
30. McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology 2006;45:1255-60.
31. Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs 2005;65:1355-65.
32. Ramanan AV Feldman BM Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes Rheum Dis Clin North Am 2002 2883357
33. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
34. Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 2013;92:25-41.
35. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011;7:664-75.
36. Schwartz T, Diederichsen LP, Lundberg IE, et al. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. RMD Open 2016;2:e000291.
37. Singh S, Suri D, Aulakh R, et al. Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India. Clin Rheumatol 2014;33:1675-9.
38. Huber AM, Lang B, LeBlanc CM, et al. Medium-and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
39. Sanner H, Gran JT, Sjaastad I, et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology 2009;48:1541-7.
40. Rasmussen AR, Wohlfahrt-Veje C, Tefre de Renzy-Martin K, et al. Validity of selfassessment of pubertal maturation. Pediatrics 2015;135:86-93.
41. Apaz MT, Saad-Magalhães C, Pistorio A, et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009;61:509-17.
42. Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
43. Feldman BM, Grundland B, McCullough L, et al. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol 2000;27:226-33.
44. Brown VE, Pilkington CA, Feldman BM, et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006;45:990-3.
45. Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2011;63:1213-23.
46. Ruperto N, Hanrahan LM, Alarcón GS, et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62.
47. Christen-Zaech S, Seshadri R, Sundberg J, et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:571-6.
48. Schmeling H, Stephens S, Goia C, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology 2011;50:885-93.
49. Tiao J, Feng R, Berger EM, et al. Evaluation of the reliability of the cutaneous dermatomyositis disease area and severity index and the cutaneous assessment tool-binary method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists. Br J Dermatol 2017.